What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
By Holly Campbell | October 15, 2018
Pharmaceutical Research and Manufacturers of America (PhRMA) member companies today announced their commitment to providing more transparency about medicine costs to help patients make more...
Read More
Americans want to know more than just the list price of a medicine—and we’re answering their call
By Robert Zirkelbach | October 15, 2018
The biopharmaceutical industry is answering the call to provide more information about medicine costs. As innovators of life-saving therapies, we recognize the importance of giving people the...
Read More
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
By Katie Koziara | October 4, 2018
According to a new report by IQVIA Institute for Human Data Science, more and more patients are asked to pay high cost sharing due to changes in benefit design. Previous analysis has shown that...
Read More
Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
By Juliet Johnson | September 24, 2018
The changes made to Part D in the Bipartisan Budget Act (BBA) that passed in February threaten the program’s successful competitive structure. While these changes closed the donut hole a year...
Read More
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
By Juliet Johnson | September 13, 2018
Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines. These...
Read More
Number of value-based contracts continues to rise
By Michelle Drozd | August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...
Read More
69 percent of patients abandon medicines when cost sharing is more than $250
By Holly Campbell | August 23, 2018
New research from the IQVIA Institute for Human Data Science shows that when cost sharing rises, patients are more likely to abandon their medicines. In 2017, 69 percent of commercially insured...
Read More
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
By Holly Campbell | July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....
Read More
New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs
By Holly Campbell | July 9, 2018
Newly released data from the Kaiser Family Foundation show out-of-pocket costs for patients with employer-sponsored health insurance rose faster than the costs paid by their insurers between 2006...
Read More
Pass-through rebates do not violate non-interference clause but they do increase savings for seniors
By Jim C. Stansel | July 2, 2018
For more than a decade, Medicare Part D has successfully provided seniors with comprehensive prescription drug coverage. Key to its success is a unique, market-based structure of private-sector...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
